MED9
Mediator of RNA polymerase II transcription subunit 9
Also known as: FLJ10193, MED25, MED9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NWA0
- Gene
- MED9
- Ensembl
- ENSG00000141026
- Chromosome
- 17
- Canonical length
- 146 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Midbody
OverviewNCBI Gene
The multiprotein Mediator complex is a coactivator required for activation of RNA polymerase II transcription by DNA bound transcription factors. The protein encoded by this gene is thought to be a subunit of the Mediator complex. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
146 residues, UniProt reviewed canonical sequence.
>Q9NWA0|MED9
1 MASAGVAAGR QAEDVLPPTS DQPLPDTKPL PPPQPPPVPA PQPQQSPAPR PQSPARAREE
61 ENYSFLPLVH NIIKCMDKDS PEVHQDLNAL KSKFQEMRKL ISTMPGIHLS PEQQQQQLQS
121 LREQVRTKNE LLQKYKSLCM FEIPKELocalizationUniProt · AlphaFold · HPA
Whether an antibody against MED9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.56
- Highest tissue expression
- 39 nTPM
Expression across tissuesHPA
Tissue
- tongue: 39 nTPM
- heart muscle: 31 nTPM
- skeletal muscle: 26 nTPM
- basal ganglia: 26 nTPM
- cerebral cortex: 26 nTPM
- liver: 23 nTPM
Single-cell type
- myonuclei: 48 nCPM
- renal connecting tubule cells: 42 nCPM
- epididymal principal cells: 37 nCPM
- renal collecting duct intercalated cells: 36 nCPM
- differentiating spermatogonia: 36 nCPM
- distal convoluted tubule cells: 31 nCPM
Immune cell
- non-classical monocyte: 13 nTPM
- plasmacytoid DC: 13 nTPM
- MAIT T-cell: 12 nTPM
- eosinophil: 12 nTPM
- naive CD8 T-cell: 12 nTPM
- NK-cell: 11 nTPM
Brain region
- cerebral cortex: 25 nTPM
- basal ganglia: 22 nTPM
- thalamus: 21 nTPM
- midbrain: 21 nTPM
- medulla oblongata: 20 nTPM
- amygdala: 19 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0.41
- gnomAD missense Z
- 0.79
- DepMap mean gene effect
- -0.69
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- positive regulation of transcription elongation by RNA polymerase II
- positive regulation of transcription initiation by RNA polymerase II
- RNA polymerase II preinitiation complex assembly
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Mediator complex, subunit Med7/Med21-like
- Mediator of RNA polymerase II transcription subunit 9
- Mediator of RNA polymerase II transcription subunit 9, metazoan
- RNA polymerase II transcription mediator complex subunit 9
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MED9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MED9 as an antibody target. Whether an autoantibody or antibody against MED9 could matter depends on whether native MED9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MED9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MED9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...